CSChengxin Shi

Chengxin Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chengxin Shi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Yang

    Department of Orthopaedics, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, 510630, China

    1 shared publication
  • Dan Liu

    Department of General Surgery, First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, China

    1 shared publication
  • Dan Shao

    Institutes of Life Sciences, School of Biomedical Sciences and Engineering and National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 510006, China

    1 shared publication
  • Fangman Chen

    National Engineering Research Center for Tissue Restoration and Reconstruction

    1 shared publication
  • Feiyu Shi

    Department of General Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

    1 shared publication
  • Feng Liu

    Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease

    by Chengxin Shi, Jianati Dawulieti, Feiyu Shi, Chao Yang, Qian Qin, Tongfei Shi, Lizhao Wang, Hanze Hu, Madi Sun, Li Ren, et al.

    A therapeutic strategy that targets multiple proinflammatory factors in inflammatory bowel disease (IBD) with minimal systemic side effects would be attractive. Here, we develop a drug-free, biodegradable nanomedicine that acts against IBD by scavenging proinflammatory cell-free DNA (cfDNA) and reactive oxygen species (ROS). Polyethylenimine (PEI) was conjugated to antioxidative diselenide-bridged mesoporous organosilica nanoparticles (MONs) to formulate nanoparticles (MON-PEI) that exhibited high cfDNA binding affinity and ROS-responsive degradation. In ulcerative colitis and Crohn’s disease mouse colitis models, orally administered MON-PEI accumulated preferentially in the inflamed colon and attenuated colonic and peritoneal inflammation by alleviating cfDNA- and ROS-mediated inflammatory responses, allowing a reduced dose frequency and ameliorating colitis even after delayed treatment. This work suggests a new nanomedicine strategy for IBD treatment.